CA2999747A1 - Methods for treating heart failure using glucagon receptor antagonistic antibodies - Google Patents

Methods for treating heart failure using glucagon receptor antagonistic antibodies Download PDF

Info

Publication number
CA2999747A1
CA2999747A1 CA2999747A CA2999747A CA2999747A1 CA 2999747 A1 CA2999747 A1 CA 2999747A1 CA 2999747 A CA2999747 A CA 2999747A CA 2999747 A CA2999747 A CA 2999747A CA 2999747 A1 CA2999747 A1 CA 2999747A1
Authority
CA
Canada
Prior art keywords
antibody
seq
subject
amino acid
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2999747A
Other languages
English (en)
French (fr)
Inventor
Hai Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Remd Biotherapeutics Inc
Original Assignee
Remd Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Remd Biotherapeutics Inc filed Critical Remd Biotherapeutics Inc
Publication of CA2999747A1 publication Critical patent/CA2999747A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/68—Plantaginaceae (Plantain Family)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CA2999747A 2015-09-04 2016-09-02 Methods for treating heart failure using glucagon receptor antagonistic antibodies Pending CA2999747A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214449P 2015-09-04 2015-09-04
US62/214,449 2015-09-04
US201562259061P 2015-11-24 2015-11-24
US62/259,061 2015-11-24
PCT/US2016/050183 WO2017040986A1 (en) 2015-09-04 2016-09-02 Methods for treating heart failure using glucagon receptor antagonistic antibodies

Publications (1)

Publication Number Publication Date
CA2999747A1 true CA2999747A1 (en) 2017-03-09

Family

ID=58188491

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2999747A Pending CA2999747A1 (en) 2015-09-04 2016-09-02 Methods for treating heart failure using glucagon receptor antagonistic antibodies

Country Status (7)

Country Link
US (2) US10765737B2 (cg-RX-API-DMAC7.html)
EP (1) EP3344279B1 (cg-RX-API-DMAC7.html)
JP (1) JP6890340B6 (cg-RX-API-DMAC7.html)
CN (1) CN108348582B (cg-RX-API-DMAC7.html)
AU (1) AU2016318097B2 (cg-RX-API-DMAC7.html)
CA (1) CA2999747A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017040986A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7005638B2 (ja) 2017-01-27 2022-02-04 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド グルカゴン受容体結合タンパク質及びその使用方法
EP3829636A1 (en) 2018-07-27 2021-06-09 NGM Biopharmaceuticals, Inc. Use of glucagon receptor antagonists with immunotherapeutic agent
JP7840511B2 (ja) 2019-02-01 2026-04-06 石▲薬▼集▲団▼巨石生物制▲薬▼有限公司 抗クローディン18抗体及びそれらの使用の方法
CN118393150B (zh) * 2024-06-27 2024-09-13 潍坊市润生畜禽良种有限公司 一种优化gcgr卵黄抗体制备的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030103983A1 (en) 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
WO2006005469A2 (en) 2004-07-15 2006-01-19 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with glucagon receptor (gcgr)
CL2007002668A1 (es) * 2006-09-20 2008-05-09 Amgen Inc Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2.
US9034883B2 (en) * 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
US8771696B2 (en) 2010-11-23 2014-07-08 Regeneron Pharmaceuticals, Inc. Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor

Also Published As

Publication number Publication date
US20200353079A1 (en) 2020-11-12
US11446376B2 (en) 2022-09-20
CN108348582B (zh) 2023-04-14
JP2018528210A (ja) 2018-09-27
AU2016318097B2 (en) 2023-04-20
AU2016318097A1 (en) 2018-04-12
WO2017040986A1 (en) 2017-03-09
EP3344279A1 (en) 2018-07-11
US20180256713A1 (en) 2018-09-13
US10765737B2 (en) 2020-09-08
CN108348582A (zh) 2018-07-31
JP6890340B2 (ja) 2021-06-18
JP6890340B6 (ja) 2021-07-14
EP3344279A4 (en) 2019-03-27
EP3344279B1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
US11446376B2 (en) Methods for treating heart failure using glucagon receptor antagonistic antibodies
US20230126271A1 (en) Degrader-antibody conjugates and methods of using same
EP2951205B1 (en) Anti-activin-a compounds for the treatment of ovarian cancer
US11447555B2 (en) Methods for treating type 1 diabetes using glucagon receptor antagonistic antibodies
KR20110074898A (ko) 염증을 치료하는 방법
JP2011526244A (ja) 炎症の処置方法
RS59354B1 (sr) Postupci lečenja nosne polipoze davanjem il-4r antagonista
CN117222663A (zh) 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
TW202317175A (zh) 用於重量管理及相關代謝病症之療法
AU2020319899A1 (en) Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics
CA2980765A1 (en) Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies
CA3041325A1 (en) Use of beta-catenin as a biomarker for treating cancers using anti-dkk-1 antibody
US20230372518A1 (en) Antimitotic tetrapeptide-antibody conjugates and methods of using same
WO2022109302A1 (en) Anti-galectin-9 antibodies and therapeutic uses thereof
JP2023539107A (ja) アクチビンaアンタゴニストによる心機能障害及びcovid-19の予防及び治療方法
US20240166759A1 (en) Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
WO2026101890A1 (en) Combinations of anti-il-27 antibodies with toripalimab and bevacizumab
CN115279393A (zh) 以介白素24或介白素20拮抗剂治疗组织纤维化和/或损伤和/或器官衰竭
CN116490520A (zh) 用于covid-19肺炎的托珠单抗和瑞德西韦组合疗法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210823

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241105

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20241224

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20241224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260220

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260223

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260421